Host-Dependent Tumorigenesis of Embryonic Stem Cell Transplantation in Experimental Stroke

Erdő, Franciska; Bührle, Christian; Blunk, James A.; Hoehn, Mathias; Xia, Ying; Fleischmann, Bernd K.; Föcking, Melanie; Küstermann, Ekkehardt; Kolossov, Eugen; Hescheler, Jürgen; Hossmann, K.‐A.; Trapp, Thorsten

doi:10.1097/01.wcb.0000071886.63724.fb

Cited by 333 publications

(273 citation statements)

References 24 publications

Supporting

Mentioning

261

Contrasting

Unclassified

Order By: Relevance

“…The formation of these tumors is a function of the degree to which the cells are selectively enriched and differentiated prior to transplantation [40,42]. However, embryoid bodies (EBs) from early stage of the culture can be contaminated with undifferentiated multipotent cells that escaped the differentiation process, permitting teratogenesis in the host [41][42][43][44]. Thus, the faster the hESCs are differentiated in vitro, the higher the risk may be of teratoma formation after transplantation [45].…”

Section: Embryonic Stem Cells As a Source Of New Medium Spiny Neuronsmentioning

confidence: 99%

Cellular Therapy and Induced Neuronal Replacement for Huntington's Disease

Benraiss

Goldman

2011

Neurotherapeutics

View full text Add to dashboard Cite

Section: Embryonic Stem Cells As a Source Of New Medium Spiny Neuronsmentioning

confidence: 99%

Cellular Therapy and Induced Neuronal Replacement for Huntington's Disease

Benraiss

Goldman

2011

Neurotherapeutics

View full text Add to dashboard Cite

“…Tumor formation was not observed for more than 220 days after injection of ESC-RPEs into a rat model [36]. Concern regarding tumorigenicity remains, however, because ESC tumors can be more virulent in homologous than in xenografted hosts, as is true for the production of inappropriate progeny types (e.g., non-neural cells after placement in the CNS) [37,38]. Immune rejection with allogenic ESC-RPE transplants can be controlled by immune suppression of the host.…”

Section: Rpescsmentioning

confidence: 99%

Stem Cells for Retinal Replacement Therapy

Stern

Temple

2011

Neurotherapeutics

View full text Add to dashboard Cite

Retinal degenerative disease has limited therapeutic options and the possibility of stem cell-mediated regenerative treatments is being actively explored for these blinding retinal conditions. The relative accessibility of this central nervous system tissue and the ability to visually monitor changes after transplantation make the retina and adjacent retinal pigment epithelium prime targets for pioneering stem cell therapeutics. Prior work conducted for several decades indicated the promise of cell transplantation for retinal disease, and new strategies that combine these established surgical approaches with stem cell-derived donor cells is ongoing. A variety of tissue-specific and pluripotent-derived donor cells are being advanced to replace lost or damaged retinal cells and/or to slow the disease processes by providing neuroprotective factors, with the ultimate aim of long-term improvement in visual function. Clinical trials are in the early stages, and data on safety and efficacy are widely anticipated. Positive outcomes from these stem cell-based clinical studies would radically change the way that blinding disorders are approached in the clinic.

show abstract

“…However, present therapies are mainly for primary or secondary prevention. Therefore, cell replacement therapies, such as those involving embryonic stem cells (ES cells; Erdo et al, 2003), neural stem cells (Modo et al, 2002a, b;Nelson et al, 2002;Savitz et al, 2002;Watson et al, 2003), and bone marrow-derived stem cells (Beck et al, 2003;Chen et al, 2001Chen et al, , 2003Li et al, 2001Li et al, , 2002Zhao et al, 2003), have the possibility of offering a novel potential treatment for stroke damage (Bjorklund and Lindvall, 2000;Kondziolka et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Primate Embryonic Stem Cell-Derived Neuronal Progenitors Transplanted into Ischemic Brain

Hayashi

Takagi

Fukuda

et al. 2006

J Cereb Blood Flow Metab

128

View full text Add to dashboard Cite

Transplantation of stem cells has the possibility of restoring neural functions after stroke damage. Therefore, we transplanted neuronal progenitors generated from monkey embryonic stem (ES) cells into the ischemic mouse brain to test this possibility. Monkey ES cells were caused to differentiate into neuronal progenitors by the stromal cell-derived inducing activity method. Focal cerebral ischemia was induced by occluding the middle cerebral artery by the intraluminal filament technique. The donor cells were transplanted into the ischemic lateral striatum at 24 h after the start of reperfusion. The cells transplanted into the ischemic brain became located widely around the ischemic area, and, moreover, the transplanted cells differentiated into various types of neurons and glial cells. Furthermore, at 28 days after the transplantation, over 10 times more cells in the graft were labeled with Fluorogold (FG) by stereotactic focal injection of FG into the anterior thalamus and substantia nigra on the grafted side when compared with the number at 14 days. From these results we confirmed the survival and differentiation of, as well as network formation by, monkey ES-cell-derived neuronal progenitors transplanted into the ischemic mouse brain.

show abstract

Host-Dependent Tumorigenesis of Embryonic Stem Cell Transplantation in Experimental Stroke

Cited by 333 publications

References 24 publications

Cellular Therapy and Induced Neuronal Replacement for Huntington's Disease

Cellular Therapy and Induced Neuronal Replacement for Huntington's Disease

Stem Cells for Retinal Replacement Therapy

Primate Embryonic Stem Cell-Derived Neuronal Progenitors Transplanted into Ischemic Brain

Contact Info

Product

Resources

About